Several human genetic factors, including red blood cell polymorphisms (ABO blood group, sickle-cell trait, G6PD deficiency) as well as point mutations in the mannose binding protein (MBP) and in the promoter regions of both the TNF-␣ and NOS2 genes, influence the severity of disease due to infection with Plasmodium falciparum. We assessed their impact on mild P. falciparum malaria, as part of a longitudinal investigation of clinical, parasitological and immunological parameters in a cohort of 300 Gabonese schoolchildren. We found the following frequencies: blood group O (0.54), sicklecell trait (0.23), G6PD deficiency (0.09), MBP gene mutations (0.34), TNF-␣ promoter mutations (at positions −238: 0.17 and −308: 0.22) and NOS2 promoter mutation (0.18). Blood group O or hemoglobin AA were associated with protection against higher parasitemia. Girls with normal G6PD enzyme activity were protected against clinical malaria attacks. In addition, we demonstrated for the first time that the mutation at position −238 of the gene coding for the promoter region of TNF-␣ was positively correlated with the level of the antibody response specific for epitopes of the antigens MSA-2 and RAP-1 of P. falciparum. Genes and Immunity (2000) 1, 435-441.
Introduction
For some years it has been clear that the genetic determination of malaria susceptibility in humans is highly polygenic, as it is for many infectious diseases. Genetic polymorphisms of the innate immune system and of the erythrocyte have namely been proposed as factors protecting against severe malaria.
1 A better knowledge of the polymorphic host genes associated with resistance to clinical malaria and/or with high parasite densities might provide new insights into disease mechanisms, and suggest new approaches for prophylactic or therapeutic interventions. 2 Although several host genetic factors related to resistance to severe malaria (cerebral malaria, severe anemia) have convincingly been listed, 3 the same is not the case for the mild expression of the disease. 4 Indeed, concerning red blood cell polymorphisms for example, no study has revealed any influence of ABO blood groups on the susceptibility to mild malaria 5 nor on the delay of reinfection after curative anti-malarial treatment. 6 Although sickle-cell trait protects against severe malaria and reduces susceptibility to mild malaria, 7 it does not appear to prevent Plasmodium falciparum infection. Lastly, the geographical overlap between the distribution of G6PD deficiency and the endemicity of malaria has suggested that G6PD deficient subjects might be protected against malaria, but field studies have yielded conflicting results. [8] [9] [10] Polymorphisms of components of the inflammatory response have been investigated more recently, and among them, polymorphisms in the promoter region of the TNF-␣ gene are the most widely studied. Results from different study sites have varied in their ability to demonstrate an impact on the clinical outcome of P. falciparum infection. [11] [12] [13] In all these studies, the TNF-␣ promoter polymorphisms appear to be related to severe expression of the malarial disease, but not to mild malaria.
We undertook a prospective longitudinal study, over a 1-year period, in schoolchildren living in an area of Gabon where malaria is highly endemic, in order to examine the relationships between malaria prevalence and malaria-related morbidity. 14 We revealed in the same cohort several associations between disease susceptibility and immune responses directed to synthetic peptides of P. falciparum asexual blood stage antigens, 15 as well as the presence of genetic regulation via the locus HLA-A, and of specific immune responses directed to epitopes of Liver Stage Antigen-1 (LSA-1) of P. falciparum. 16 In the present study, we determined the prevalence rates of several red blood cell genetic polymorphisms (blood group, sickle cell trait, G6PD) which are known to be present at significant frequencies in sub-Saharan Africa. 4 We also investigated the more recently described genetic polymorphisms of selected components of the inflammatory response, including polymorphisms of promoter regions of TNF-␣ and NOS2, and of the mannose binding protein (MBP). Lastly, we analyzed the relationships between these genetic factors and clinical or parasitological presentation of P. falciparum mild malaria, as well as specific immune responses characterized by antibody responses directed to peptides from P. falciparum asexual blood stage antigens.
Results
This study aimed to investigate the relationships between several host genetic factors and the clinical, parasitological and immunological status vis-à-vis P. falciparum malaria in the school-going population of 300 children in the Gabonese village of Dienga. In the whole population sample, prevalence rates of ABO blood groups (group O: 54%, group A: 27%, group B: 17% and group AB: 1%) and sickle-cell trait (23%) were evaluated. Concerning G6PD, 60 subjects (22%) presented the allele A−, and at least 24 of them (9% of the whole cohort) were phenotypically deficient in G6PD as they included 22 hemizygote males and two homozygote females. Gene polymorphisms in the promoter region of TNF-␣ revealed prevalence rates of 17% (for TNF −238 A allele) and 22% (for TNF −308 A allele) of children harboring mutations, mainly in the heterozygous state as only 1.9% and 2.3% of children were homozygous for these mutations, respectively. A point mutation in the promoter region of NOS2 was present in 18% of children, mainly in the heterozygous state (except for two children). At least one MBP gene mutation was present in 34% of the children, with an overall gene frequency of 0.02 and 0.16 for mutations at codons 54 and 57, respectively. The mean geometric parasite density (95% confidence interval) of the 1036 positive blood smears detected among the totality of the smears collected during 16 cross-sectional surveys for the detection of asymptomatic infections was low, with 203 (180-230) P. falciparum parasites per l of blood. The individual ability to control the parasite density was expressed by the geometric mean of date-and age-adjusted parasitic densities (GMAPD), as presented in Table 1 . GMAPD were lower in children with blood group O than in those with non-O blood groups (Student's unpaired t-test, P = 0.043). Clinical and parasitological data did not differ when comparing children with and without blood group A, the second most prevalent blood group in the population sample. Children carrying sickle-cell trait presented higher GMAPD compared to those with normal hemoglobin (Student's unpaired t-test, P = 0.031). This was accompanied by a higher mean prevalence rate of P. falciparum infection determined during the 16 cross-sectional surveys among HbAS (34.5%) than HbAA (26.8%) children (Chi-square test, P Ͻ 0.0001). We revealed a trend for those with both blood group O and AA haemoglobin to harbour lower parasite densities than other individuals (n = 106, Student's unpaired t-test, P = 0.055). This trend was reinforced when considering children р10 years of age (n = 53, Student's unpaired t-test, P = 0.045).
The distribution of host genetic types among clinicallyclassified children showed that females tended to be more protected than males (Chi-square test, P = 0.06), and after having split our cohort into two age classes, including children р10 years (n = 164) and children Ͼ10 years (n = 136), this difference was found significant among females Ͼ10 years (Chi-square test, P = 0.015). Carriers of the G6PD A− allele were more frequent among unprotected than protected females (Chi-square test, P = 0.026). This relation was confirmed when restricted to heterozygote G6PD A-/A females, ie, two and seven individuals in protected and unprotected groups, respectively (Chi-square test, P corrected = 0.038). The fact that females tended to be more protected than males appeared to be attributable to their normal G6PD genotype (n = 31 both protected and non-G6PD deficient females, Chi-square test, P = 0.002), no difference being observed between females and males with mutated G6PD genotypes.
The analysis of the relationships between host genetic factors and anti-peptide antibody responses is presented in Table 2 , and revealed higher levels of antibodies to NTSDSQKE (peptide from MSA-2) and LTPLEELYP (peptide from RAP-1) in subjects presenting the TNF −238 A allele than in others (Mann-Whitney U-test, P = 0.008 and P = 0.009, respectively). When taking age into account, this observation was confirmed for children Ͼ10 years (Mann-Whitney U-test, P = 0.033 and P = 0.013, respectively).
Discussion
The present study among 300 schoolchildren from the Gabonese village of Dienga revealed several associations between host genetic factors and either the clinical, parasitological or immunological status of the children as regards P. falciparum malaria. Namely, the presence of blood group O or hemoglobin AA was associated with more efficient control of parasite multiplication. Girls with normal G6PD activity were protected against clinical malaria. Lastly, the mutation at position −238 of the gene coding for the promoter region of TNF-␣ was related to a higher antibody response to epitopes of the antigens MSA-2 and RAP-1 from P. falciparum. Explanations for these observations are discussed according to the nature of the genetic factors investigated, ie, red blood cell polymorphisms as well as polymorphisms of several components of the inflammatory response.
Two earlier studies conducted in Zimbabwe 17 and Gabon 5 have shown that patients with blood group A were at a significantly greater risk for severe malaria than others. Conversely, a small but significant association of blood group O with resistance to severe malaria was found in The Gambia. 4 The association of rosetting rates with severe malaria, and the fact that rosette formation is more common with blood group A 18 and less common with blood group O, 19 may offer an explanation for these observations, or may simply indicate other host-parasite interactions yet to be defined. Although conflicting results have been obtained concerning the influence of blood groups on parasite densities, 5, 20 we did observe lower parasite densities in those with blood group O compared to non-O subjects, substantiating the argument for a protective effect of blood group O against P. falciparum malaria.
The absence of any relationship between sickle-cell trait and clinical protection among our cohort with a mean age of 10 years was not surprising, since this gen- etic trait has its principal impact during the first years of life, before the superposed effect of acquired immunity. 21 Indeed, in asymptomatic children, mean parasite densities have been shown to be higher in HbAS than HbAA children less than 5 years old, 22 but similar in older individuals. [23] [24] [25] In the present study, higher GMAPD values in HbAS children may in part be attributed to the higher mean prevalence rate of P. falciparum infection among these children during the 16 cross-sectional surveys. Moreover, in holoendemic areas of Ghana 26 and The Gambia, 27 children with a moderate parasite count (less than 50/l in Ghana and 500/l in The Gambia) as observed in our sample, were more commonly seen among HbAS than in HbAA controls.
Conversely to sickle-cell trait, the implication of G6PD deficiency in protection against malaria has never been clearly established. G6PD is a cytoplasmic enzyme, allowing cells to withstand oxidant stress, that is encoded by the probably most polymorphic gene in humans, located on the X chromosome. In Africa, G6PD is represented by three major variants, G6PD B (normal), G6PD A (90% enzyme activity) and G6PD A− (12% enzyme activity). 28 A large case-control study revealed an association between G6PD A− and a significant reduction in the risk of severe malaria for both G6PD female heterozygotes and male hemizygotes. 10 Other results suggested that female heterozygotes, but not male hemizygotes
Genes and Immunity were protected against high parasite densities in Nigerian children with acute malaria, 8 and more precisely, that only G6PD A−/B heterozygote females gained an advantage against morbidity rates and parasitemia. 29 Unfortunately, this finding could not be further corroborated in the same population, 9 and it was rather suggested that protection against malaria was not afforded by G6PD deficiency itself, but by a related phenomenon to be identified. 30 In the present study, no difference, either in susceptibility to malaria attack or in the ability to control parasite density was revealed between normal and G6PD A− males, thus confirming some previous data. 8, 9 It was, however, striking to observe that heterozygote G6PD A−/A females were more likely to present with a malaria attack than their G6PD non-deficient counterparts. This finding suggests that the G6PD A−/A heterozygote combination may be a susceptibility factor for clinical malaria, rather than an inoperative genetic factor. 29 It is however difficult to draw decisive conclusions for several reasons. Firstly, the small sample size of females did not allow a determination of the presence of possible linkage between the G6PD locus and other genetic factors which may be involved. 30 Secondly, the location of the G6PD gene on the X chromosome and the subsequent variable X-chromosome inactivation, implies that the expression of G6PD deficiency differs markedly among heterozygote females, 31 and therefore that these females do not constitute a homogeneous group.
We investigated the impact of polymorphisms of products of the inflammatory response on susceptibility to mild malaria by assessing known polymorphisms in the TNF-␣ and NOS2 gene promoter regions, as well as in the MBP gene. TNF-␣ is a proinflammatory cytokine that provides rapid host defense against infection but is detrimental or fatal in excess. Support for the role of TNF-␣ in the pathogenesis of malaria lies in the finding that polymorphisms in the promoter region of the TNF-␣ gene govern the outcome of infection in terms of disease severity, although there are conflicting results from different study sites. Thus, a G to A point mutation at position −238 relative to the TNF-␣ transcriptional start site has recently been found to be associated with severe malarial anemia in The Gambia, 12 but with protection from cerebral malaria in Kenya. 11 The G to A point mutation at position −308, another TNF-␣ gene polymorphism frequently encountered in sub-Saharan Africa, is related to an increased risk of cerebral malaria in homozygotes in The Gambia, 32 and in heterozygotes in a more recent study in Sri Lanka. 13 In all these studies, TNF-␣ promoter polymorphisms were related specifically to severe but not mild malaria, which is consistent with the absence, in our study, of differences between children classified either according to their clinical status or to their ability to control P. falciparum parasite densities. Hitherto TNF-␣ gene expression has not been related to any variation in cytokine production, thus the −238 and −308 polymorphisms may serve as markers for a functional polymorphism elsewhere in the TNF-␣ gene or in another immunologically relevant gene situated nearby. 12 TNF-␣ is also critical in the development of the humoral response as an autocrine B cell growth factor, 33 representing an important mediator of B cell regulation during several parasitic diseases including malaria. 34 In our study, the TNF −238 A allele was linked to high levels of plasma antibodies directed to peptides NTSDSQKE and LTPLEELYP from the MSA-2 and RAP-1 antigens of P. falciparum, respectively. It is of particular note that clinically protected children in the same cohort presented higher specific antibody levels to these same peptides, but not to others, compared with unprotected children. 15 Although the TNF −238 A allele was not directly related to clinical protection against mild malaria (Chi square test, P Ͼ 0.05), this genetic polymorphism could be involved in protection against mild disease through its influence on the production of protective antibodies to asexual blood stages. This is the first time that a defined TNF-␣ gene promoter polymorphism has been found to be related to enhanced antibody responses to specific malarial antigens. We would propose one of two possible explanations for this finding. Firstly, a second polymorphism, TNF −376 A, which is frequently found in linkage disequilibrium with TNF −238 A, is related to enhanced secretion of TNF 11 and might be responsible for increased antigen-or T-cell-mediated B-cell stimulation and proliferation. 33 Alternatively, the TNF −238 A allele may preferentially induce TNF-␣ in its soluble rather than its membrane-bound form. These different forms of TNF-␣ bind to different TNF receptors named TNFR1 (soluble form) and TNFR2 (membrane-bound form). 34 Interestingly, it was recently demonstrated that a full IgG response, mainly mediated by follicular dendritic cells, depends on a signal delivered through TNFR1. 35 Whether mediated by quantitative or qualitative changes in TNF-␣ production, the relationship we have described here between the TNF −238 A allele and enhanced antimalarial antibody levels, themselves associated with clinical protection, is a novel one. Its significance in the context of vaccine development, however, remains to be clarified, because of the highly complex regulatory mechanisms controlling the synthesis of this cytokine, which can have both beneficial and deleterious effects for the human host.
Another polymorphism of interest with regard to susceptibility to malaria is that of the promoter region of NOS2. Carriers of the point mutation at position −969 of this region tended to be clinically protected, confirming the presence of an association between this polymorphism and a decreased severity of disease as well as of a prolonged time to first reinfection. 36 Conversely, polymorphisms in a microsatellite region in the promoter region of NOS2 have been associated with fatal cerebral malaria. 37 These genetic studies have led to similarly conflicting results as have biological observations, according to which nitric oxide (NO) was first identified as a potential cause of neurosuppression leading to cerebral malaria. 38 However, increased expression of NOS2 in PBMC, and particularly in monocytes, 39 leading to increased NOS2-derived NO synthesis, is associated with protection against clinical disease. 40 It seems therefore too early to establish a definitive causal association between NOS2 polymorphisms and malaria susceptibility.
MBP is a member of the collectin family of proteins, which are constituents of the innate immune system, acting therefore against multiple pathogenic organisms. 41 MBP is thought to be more effective at an early age, before effective acquired immune responses have developed, and low plasma concentrations of nonfunctional MBP have been attributed to mutations in the coding region of the MBP gene. 42 The frequencies of MBP gene mutations in our population are consistent with those reported in a case-control study conducted in a different area of Gabon, showing that MBP gene mutations are present at a higher frequency in young children with severe rather than mild malaria. 43 In the study reported here, we could find no difference in the distribution of MBP mutations according to the clinical or parasitological status of the subjects, confirming previous findings. 44 This could reflect the fact that our study focused on mild rather than severe malaria, and on an older agegroup of children compared with the other Gabonese study. 43 Overall, in this study we have demonstrated that blood group O and hemoglobin AA are associated with protection against parasite multiplication, and that girls with normal G6PD activity are protected against clinical malaria. In addition, we found that the mutation at position −238 of the promoter region of the TNF-␣ gene was related to higher levels of antibodies specific for epitopes of the antigens MSA-2 and RAP-1 of P. falciparum. We have to take into account that interactions between host and parasite polymorphisms contribute to add a further layer of complexity in the associations described here. Namely, a previous work performed on genetic polymorphisms of P. falciparum among asymptomatic children from the same Gabonese cohort, demonstrated that sickle-cell trait carriers harbored more multiple P. falciparum parasite genotypes, 45 which allelic distribution, based on the analysis of MSP-1 gene polymorphism, was different as compared with HbAA children. 46 These particular associations might be able to affect disease susceptibility. Clearly, host genetic factors have weaker and less influential effects on mild compared with severe malaria, and their impact is thus more difficult to demonstrate in epidemiological studies. This is reflected in the fact that the data presented here are not completely consistent with those reported in previous studies of severe malaria, which further underscores the complexity of host resistance to falciparum malaria.
Materials and methods

Study area
The study was conducted in Dienga, a village of 1200 inhabitants located in South Eastern Gabon, near the 439 Congo border. This village is situated in a rain forest area, and malaria is highly endemic with peaks of transmission occurring at the end of the rainy seasons from December to March and in July-August (Elissa N, unpublished data).
Subjects
A clinical, biological and parasitologic follow-up, details of which have been described elsewhere, 14 was carried out from February 1995 to March 1996 (except during the school summer holidays) among the 300 children (169 males and 131 females, mean age ± s.d. = 10.4 ± 2.7 years) attending the primary school in Dienga. Clinical data allowed protected and unprotected children to be distinguished. Protected children (n = 76) were defined as those who, during the whole survey period, never presented with a febrile episode (defined by an axillary temperature Ͼ37.5°C) associated with either a P. falciparum parasitemia Ͼ400/l or 4-aminoquinoline metabolites in their urine. 47 Unprotected children (n = 82) were defined as those who presented with at least one malaria attack, defined by the association of fever with P. falciparum parasitemia Ͼ5000/l. The other children (n = 142) remained unclassified. After obtaining informed consent from all individuals and/or their parents, venous blood samples were collected into Vacutainer EDTA tubes at the beginning of the follow-up for the determination of human genetic factors (n = 279 children) and at the end of the follow-up period for the immunologic assays (n = 229 children). Ethical clearance for the study was given by the local ethic committee, the Ministry of Public Health, the Governor of the Province, and the local Prefet.
Parasitologic measurements
During the follow-up, 16 twice-a-month thick blood smears were prepared for the detection of asymptomatic malaria infection. All thick blood smears were Giemsastained and examined against 200 leukocytes if positive or against 400 leukocytes prior to be declared negative. Parasite densities (PD) were recorded as the number of parasites/l of blood, assuming an average leukocyte count of 8000/l. Each value of PD was simultaneously adjusted to age and date of sampling by calculating the ratio of the individual parasite density (PD+1) to the geometric mean of all (PD+1) values recorded at each date of sampling in the group of children of same age. For each child who presented at least six recorded thick blood smears (n = 275 children), the GMAPD was calculated. For the need of the statistical analysis, logtransformed values of the GMAPD were considered. 
Genes and Immunity
Human genetic factors
At initiation of the study, blood group was determined by serology and sickle-cell trait was detected by hemoglobin electrophoresis. Gene polymorphisms of G6PD, MBP as well as those of TNF-␣ and NOS2 promoter regions were analyzed at the molecular level, using different methods based on PCR techniques. 48 The common African G6PD A− allele, as well as polymorphisms in the promoter regions of both TNF-␣ and NOS2 genes were detected by PCR-RFLP methods. Each mutation created or abolished a specific restriction enzyme site. The primers and enzymes used in this study are listed in Table  3 . Mutations in codons 54 and 57 of MBP were detected by the DGGE (Denaturing Gradient Gel Electrophoresis) method as described elsewhere. 49 
Antibody measurements
Five synthetic peptides were used, representing B cell epitopes from conserved and semi-conserved regions of P. falciparum asexual blood stages. These peptides were purchased from the Pasteur Institute (Paris, France) and were LNDITKEYEKLLNEI (residues 521-535) from the merozoite surface antigen-1 (MSA-1), SNTFINNA (residues 27-34) and NTSDSQKE (residues 213-220) from the merozoite surface antigen-2 (MSA-2), LTPLEELYP (residues 202-210) from the rhoptry-associated protein-1 (RAP-1), and K(EENVEHDA) 4 (residues 892-924) from the Pf155/ring-infected erythrocyte surface antigen (RESA). Anti-peptide antibodies were tested by ELISA, as previously described. 15 Results were expressed in arbitrary units (AU) according to reference positive and negative control plasmas, and the thresholds for positivity were set at 19.1 AU for LNDITKEYEKLLNEI, 2.9 AU for SNTFINNA, 7.7 AU for NTSDSQKE, 10.5 AU for LTPLEELYP and 29.2 AU for K(EENVEHDA) 4 , as determined from the mean reactivities +2 s.d. of Ͼ50 plasmas from non-immune subjects.
Statistical analysis
Differences in proportions were analyzed using Chi square test or Fisher's exact test according to sample sizes. Differences in means were tested by Student's unpaired t-test on linear or log-transformed values. When variable distribution was not normalized by logtransformation, the non-parametric Mann-Whitney U-test was employed. Statview 4.5 (Abacus Concept, Berkeley, CA, USA) was used for these calculations. For all tests, P values Ͻ0.05 were considered significant.
